Introduction
Protein tyrosine phosphatase a (PTPa) belongs to a large family of transmembrane receptor protein tyrosine phosphatases. PTPa has a short (123 amino acid) hyperglycosylated extracellular domain [1] , a transmembrane domain, and an intracellular domain with two catalytic domains. Most of the catalytic activity of PTPa is attributable to the membrane-proximal D1 domain [2, 3] . To date, no extracellular ligand for PTPa has been identified [1, 4] . However, the extracellular domain of PTPa binds to contactin, and these two proteins together may function as a receptor complex [5] . PTPa dephosphorylates tyrosine 527 of Src and activates c-Src in vitro and in vivo [3, 6, 7] . PTPa overexpression enhances endogenous c-Src kinase activity in rat fibroblasts by 6 folds and causes cellular transformation. These transformed cells are tumorigenic in nude mice [6] . Similar findings have been confirmed using a tet-off inducible expression system in murine NIH3T3 cells [7, 8] .
PTPa is a cell-cycle-specific activator of Src during mitosis [8, 9] . Genetic deletion of PTPa completely blocks the normal mitotic activation of Src and Fyn kinases [8] . Dephosphorylation of pTyr527 in PTPa overexpressing P19 embryonal carcinoma cells activates c-Src and induces neuronal differentiation [10] . Furthermore, PTPa 2/2 cells derived from knock-out mice exhibited increased Src and Fyn tyrosine 527 phosphorylation and decreased kinase activity [11, 12] as well as deficiencies in integrin-mediated signaling and reduced rates of spreading and migration on fibronectin substrates [12, 13] . These phenomena are consistent with the results observed in Src 2/2 , Fyn 2/2 , and Yes 2/2 triple-knockout cells [14] . Together, these findings strongly suggest that PTPa is a major physiological regulator of Src family members in vivo.
In NIH3T3 cells, approximately 20% of PTPa is phosphorylated on Tyr789, a residue close to its COOH terminus [15] [16] [17] [18] . This phosphorylated residue is constitutively bound to Grb2 via the its c-terminal SH2 domain and is not required for PTPa to dephosphorylate generic substrates such as tyrosine-phosphorylated Raytide peptide or myelin basic protein (MBP) [7, 19, 20] . Phosphorylation of Tyr789 of PTPa is required for activation of Src by dephosphorylating pTyr527 via pTyr789 binding to the SH2 domain ( phosphotyrosine displacement mechanism) [7, 8] . The binding of Grb2 to pTyr789 of PTPa blocks the displacement of pTyr527 of Src and prevents PTPa-mediated Src activation. This suggests that changes in Grb2 binding may be an important regulatory mechanism of PTPa activity, and indirectly of Src activation in vivo.
PTPa can be phosphorylated at Ser180 and Ser204 by protein kinase C (PKC) in vitro and in vivo [19] [20] [21] . Phosphorylation of these sites increases the catalytic activity of PTPa towards generic substrates by 2-3 folds [10, 19] . Furthermore, phosphorylation of PTPa at these two sites requires its co-association with PKCd and PI3 kinase [21] . The increase in Src activity is due to the direct phosphorylation and activation of PTPa by PKCd [22] .
Increased Src kinase activity has been observed in a number of human cancers, particularly breast cancer [23] . Src is mutated in only a small fraction of colon cancer cells [24] , and rarely, if ever, in human breast cancer cells. It is likely that an aberrant upstream regulator drives Src activity in these cells.
Src activation is often accompanied by overexpression of epidermal growth factor receptor (EGFR) family members, including HER2, erbB2, and neu, which together contribute to the progression and development of many cancers, particularly those in breast tissue [25, 26] . Previous studies have shown that the SH2 and SH3 domains of c-Src are also required to contribute negative regulation of Src kinase activity when the C-terminal Tyr527 is phosphorylated. Src Tyr213 phosphorylation by the ErbB2/HER2 protein tyrosine kinase in MCF7 human breast cancer cell line leads to Src activation in vitro [27] , suggesting that phosphorylation of Tyr213 blocks the ability of the Src SH2 domain to bind to Tyr527.
PTPa mRNA levels are increased in some solid colon tumors by 2-10 folds compared with normal tissue (10/14) [28] and overexpression of PTPa may be a general marker for proliferation or de-differentiation of squamous cell carcinoma [29] . Overexpression of PTPa was observed in about 30% of breast cancers [30] . However, one study reported that overexpression of PTPa correlates with low tumor grade, decreased tumor cell growth, and metastasis [30] , indicating a potential negative regulatory role. In several cancer cell lines or tissues, dephosphorylation of Src on pTyr527/530 has also been correlated with either elevated PTP1B [31] or SHP1 [32] phosphatase activity. Moreover, inhibition of PTPa (or Src) by RNAi induces apoptosis and inhibits the growth of estrogen nonresponsive breast cancer cell lines [33] . Recently, a splice mutant RPTPa245, which was cloned in all three human tumor types, has been shown to induce dephosphorylation of Src. Overexpression of the mutant RPTPa245 in fibroblasts activates Src and leads to cellular transformation and tumorigenesis in nude mice [34] .
Herein we test the hypothesis that targeting PTPa may offer a novel therapeutic approach in certain breast cancers. We observe that the treatment of BT-20 and SKBR3 breast cancer cell lines with epidermal growth factor (EGF) induces PTPa-mediated Src activation via phosphorylation of PTPa Ser180 and/or Ser204 and the dissociation of the PTPa-Grb2 complex and increased association of PTPa with Src. Moreover, we show that a specific PKCd inhibitor or knockdown of PKCd by siRNA or overexpression of PTPaS180A/S204A mutant reduces PTPa activity by diminishing EGFR-mediated Ser180 and/or Ser204 phosphorylation. This suggests that PTPa may be a viable target in certain breast cancer.
Materials and Methods
Antibodies Anti-PTPa (7091), anti-PTPa D2 (7054) polyclonal antibodies, and anti-Src mAb327 monoclonal antibody [35] were previously described. Anti-Src mAb 2-17 was from Quality Biotech (Camden, USA) and anti-HA tag rabbit polyclonal antibodies, anti-PKCd (c-17) and anti-Grb2 polyclonal antibody were from Santa Cruz Biotechnology (Santa Cruz, USA). Anti-PTP1B (P18020) monoclonal antibody was from BD Biosciences (San Jose, USA). Anti-pTyr antibody, anti-pTry527, anti-pTyr416, and anti-pY789 antibodies were from Cell Signaling Biotech (Boston, USA). HRP-conjugated secondary antibodies for immunoblots were from Jackson ImmunoResearch (West Grove, USA). GammaBind Sepharose (used with Src monoclonal antibody) was from Amersham Biosciences (Piscataway, USA). Anti-pSer180/pSer204 and anti-pSer204 polyclonal antibodies used for immunoblotting detection of phosphorylated PTPa were previously described [3] . Although the pS180 peptide used to generate the pS180/pSer204 antibody only measured pSer at position 180, tests with wild-type (wt) PTPa (S180A), wt PTPa (S204A), and wt PTPa (S180A/S204A) showed that this antibody reacted with both pSer180 and pSer204, but not with other phosphoserines [9, 36] . Thus, this antibody was used to detect combined level of phosphorylation at 180 and 204 sites.
Immunoprecipitation and immunoblotting
Cells were washed with Dulbecco's modified Eagle's medium (DMEM), trypsinized, plated into medium, and grown for 16 -18 h (80%-90% confluence) before harvesting. Cells were washed twice with ice-cold phosphate buffered saline (PBS) and lysed in 0.5 ml of lysis buffer as described [7] for 20 min at 48C with rocking. Whole cell lysates were centrifuged for 30 min at 28,000 g at 48C and total protein concentrations were measured using the Bio-Rad DC protein assay.
Cells lysates (30 mg of protein) or immunoprecipitates were resolved by 9% or 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis. Proteins were transferred to Immobilon-P polyvinylidene membrane (Millipore, Bedford, USA) and blocked with either TBST (Tris-HCl pH 7.2, 150 mM NaCl, plus 0.1% Tween 20) containing 3% bovine serum albumin for monoclonal antibodies or PBST (PBS, 0.05% Tween 20) containing 3% non-fat milk for polyclonal antibodies as described previously [7] .
Cell lines, cell culture, siRNA transfection, and reagent All cell lines were purchased from ATCC (Manassas, USA). All cells were grown in monolayer culture in DMEM (containing 4.5 g/l glucose and 2 mM glutamine) supplemented with 10% fetal bovine serum, and penicillin/streptomycin I (100 units/ml and 100 mg/ml, respectively). Cells were maintained at 378C, 10% CO 2 , 90% humidity. siRNA (PTPa-2, PTPa-2 mutant, PTP1B, and PKCd) transfection was described previously [33, 37] except PTP1B mutant 5 0 -AAUGCAGUGUGACAGUUAGAAdTdT-3 0 and PKCd mutant 5 0 -GCCUCAAGAUUCACGACUAUUdTdT-3 0 . The positions of the mutations are indicated in italics. Cells were assayed for colony formation in 0.3% soft agarose. For pcDNA3PTPaS180A/S204A mutation, a 2.4 kilobase pair HindIII-HindIII fragment containing the S180A and S204A mutants of the wt coding sequence was purified from pNPTPaS180A/S204A plasmid.
Transformation assay
Cells were plated in 60-mm dishes in growth medium without antibiotics at 30%-40% confluence, and after 24 h (60%-70% confluence) cells were transfected with PTPa2, mutant, PTPa2 siRNA, PTP1B, or mutant PTP1B siRNAs, respectively, in the absence or presence of EGF (10 ng/ml). After 24 h, cells were trypsinized, and 500 cells were plated in 60-mm dishes in medium containing 0.3% soft agarose (in duplicate) and colony formation was assayed after 21 days as previously described [7, 33] .
Phosphatase assay
Lysates containing either 1 mg (cells that did not overexpressed PTPa) or 200 mg (PTPaS180A/S204A-overexpressed BT-20 cells) of total proteins were incubated with anti-PTPa D2 polyclonal antibody. PTPa immunoprecipitates were washed three times with lysis buffer and once with phosphatase buffer (50 mM immidazole pH7.2, 5 mM DTT), then resuspended in150 ml of phosphatase buffer. Ten micromiliters of the immunoprecipitate was incubated in a total volume of 25 ml of phosphatase buffer containing 6 mg of tyrosine phosphorylated MBP as described previously [7] .
Src kinase assay Src kinase assay was carried out as previously described [7] . In brief, lysates containing 500 mg of total protein were incubated with an anti-Src mAb327 for 2 h at 48C, followed by incubation with GammaBind Sepharose beads for 1 h with rotation. Immunoprecipitates were washed with RIPA buffer containing 0.5 M NaCl, and then twice with lysis RIPA. Immunoprecipitates were assayed for Src activity by phosphorylating acid-denatured enolase as described previously [7] . Results were visualized by autoradiography or by phosphorimager analysis and 32 P incorporation was quantitated using NIH Image (Mac) software.
PTPa-Src in vivo association assay BT-20 and SKBR-3 cells were lysed in the lysis/binding buffer [7] used by Harder et al. [3] . Clarified lysates were incubated with either 0.2 ml of anti-Src mAb 2-17 or 3 ml of anti-PTPa D2 antibody as specified for 2 h at 48C , and immunocomplex were bound to Protein A beads or GammaBind Sepharose (mAb 2-17) beads for 1 h with rotation. Immunoprecipitates were washed three times with binding buffer and immunoblotted as indicated.
Grb2 binding assay
Grb2-PTPa co-immunoprecipitations were performed as described [8] . Cells were lysed in binding buffer (50 mM Tris-HCl pH 7.2, 50 mM NaCl, 10% glycerol, 2 mM EDTA, 50 mM NaF, 1% NP40, 1 mM Na 3 VO 4 , 10 mg/ml aprotinin, 10 mg/ml leupeptin). Lysates containing 500 mg total cell protein were incubated with 2 mg anti-Grb2 antibody for 2 h at 48C and immune complexes were bound to protein A-sepharose beads for an additional 1 h with rotation. Immunoprecipitations were washed three times with binding buffer and immunoblotted as indicated.
Results
EGF treatment results in decreased PTPa-Grb2 binding, increased PTPa-Src association, and Src activation We and others have reported that Src activity in several human breast cancer cell lines depends on tyrosine phosphatase activity [31, 33] . The phosphotyrosine displacement model [7] predicted that decreased binding of Grb2 to PTPa will lead to Src pTyr527/530 dephosphorylation. To determine whether PTPa plays an important role in regulating Src activity in these cells, PTPa/Src association and PTPa/ Grb2 association were investigated. Endogenous PTPa was immunoprecipitated from breast cancer cell lines BT-20, SKBR3 [ Fig. 1(A,C,E) ], MDA-MB-231, MDA-MB435s, and MCF-7, as well as normal breast MCF-10A and NIH3T3 cells. The decreased association of PTPa with Grb2 was not observed in these cells (data not shown). Using Grb2 IP co-immunoprecipitation techniques, we found that PTPa-Grb2 binding decreased by 60% -90% at 5-10 min after EGF treatment, and returned to normal after 20 min [ Fig. 1(A) , panels a and g; Fig. 1(B) ; Fig. 1(C) , panels b and h; Fig. 1(D) ]. To test whether PKCd is responsible for phosphorylating PTPa in EGF-treated cells, a similar experiment but with pharmacological inhibition of PKC was performed. We found that rottlerin, an inhibitor of PKCd, at low concentrations (3 -6 mM) [38] blocked the dissociation of PTPa from PTPa/Grb2 complex in these cell lines [ Fig. 1(C,E) ]. Moreover, the PTPa-Src interaction was inhibited by rottlerin treatment [ Fig. 1(C) , panels f and l; Fig. 1(E) , panels c and g]. Thus, rottlerin blocked the interaction between PTPa and Grb2 while promoting PTPa-Src interaction, suggesting that the switch of PTPa/Grb2 to PTPa/Src is mediated by PKCd.
We next assessed Src activity after EGF treatment and found that Src activity was increased by 2.5-4.0 folds after 5-10 min of EGF treatment and returned to normal by 20 min [ Fig. 1(F) , panels a and e]. Correspondingly, Src tyrosine phosphorylation at pTyr527/530 was reduced with a similar kinetics [ Fig. 1(F) , panels b and f ] after EGF treatment without a change in pTyr416/419 phosphorylation Fig. 1(A) . The amount of PTPa bound normalized the amount bound for 0 min is shown. Error bars indicate the SEM from three experiments. *P , 0.05, **P , 0.01, compared with EGF treatment for 0 min. (C) As in (A), except that lysates were immunoprecipitated with anti-PTPa D2 (7054) antibody, and immunoblotted with anti-PTPa (7091) antibody ( panels a, d, g, and j), anti-Grb2 antibody ( panels b, e, h, and k) and anti-Src mAb 327 ( panels c, f, i, and l). (D) As in (B), except that lysates were immunoprecipitated with anti-PTPa D2 antibody. Error bars indicate the SEM (three experiments). *P , 0.005, **P , 0.001 compared with EGF treatment for 0 min. (E) As in (C), except that lysates were respectively immunoprecipitated with anti-Src mAb 2-17 and immunoblotted with anti-PTPa antibody ( panels a, c, e, and g) and anti-Src mAb327 ( panels b, d, f, and h). (F) As in (A), except that lysates were respectively immunoprecipitated with anti-Src mAb 327 and then divided into four portions. One aliquot (10% of immunoprecipitate) was incubated with acid-denatured enolase and [g 32 -P] ATP in kinase buffer for 10 min (i.e. within the linear reaction/time regime) at 258C, separating the reaction products by electrophoresis and autoradiography ( panels a and e); the other three equal aliquots were immunoblotted with either anti-pY527/530 antibody ( panels b and f ) or anti-pTyr416/419 ( panels c and g) or anti-Src monoclonal antibody ( panels d and h). IP, immunoprecipitate; IB, immunoblot. Results are repeated in three independent experiments. The positions of molecular weight markers (in kDa) are indicated.
[ Fig. 1(F), panels c and g] . This is consistent with previous results, showing that PTPa dephosphorylates both pTyr416/ 419 and pTyr527/530 [6, 7] , leading to Src kinase activation [6, 7, 10] . These results indicate that the EGF treatment activates Src by promoting dissociation of PTPa from Grb2 interaction while promoting PTPa-Src association.
EGF treatment induced PTPa serine phosphorylation, and increased phosphatase activity of endogenous PTPa PTPa is phosphorylated at two serines, Ser180 and Ser204, in its juxtamembrane region [20] . These residues lie within the consensus sequence for protein kinase C (PKC) phophorylation sites, and can be phosphorylated by PKC in vitro. Treatment of cells with 12-0-tetradecanoylphorbol-13-acetate, a potent activator of PKC, increases phosphorylation at these sites [19] [20] [21] . The increase of PTPa phosphatase activity suggests that phosphorylation of the regulatory sites might be involved. To investigate whether EGF treatment activates PTPa by phosphorylating Ser180 and/or Ser204, PTPa was immunoprecipitated from BT-20 and SKBR3 cells treated with EGF and analyzed for phosphorylation using anti-pSer204 antibodies [ Fig. 2(A) , panels a and e] and anti-pSers180/204 antibodies [ Fig. 2(A) , panels b and f]. Our results indicate that there is enhanced phosphorylation of Ser180 and Ser204 but not of Tyr789 [ Fig. 2(A) , panels c and g] and this correlates with an increase in the catalytic activity of PTPa.
To ascertain the effect of EGF on PTPa activity, endogenous human PTPa was immunoprecipitated from the BT-20 and SKBR3 breast cancer cell lines. Aliquots of the immunoprecipitates were incubated with the non-specific substrate MBP, which was pre-phosphorylated by v-Src using [g-32 p] ATP. Specific PTPa phosphatase activity was determined by measuring the relative amounts of 32 P released per molecule of PTPa after 5-min incubation. A 2-2.5-fold increase of PTPa phosphatase activity was observed at 5-10 min after EGF treatment [ Fig. 2(C,D) ], concordant with the phosphorylation at Ser204 [ Fig. 2(B) , panels a and e]. This suggests that EGF-mediated PTPa activation might require serine phosphorylation. As expected, rottlerin [ Fig. 2(C,D) ], or PKCd siRNA treatment (but not the PKCd mutant siRNA) [ Fig. 2(F) , panel c] blocked the activation of PTPa activity [ Fig. 2(E) ] while decreasing PTPa serine phosphorylation [ Fig. 2(F), panel a, lanes 4-6 and panel c, lanes 1-3] . In addition, the overexpression of PTPaS180A/S204A, a mutant which lacks two PKC phosphorylation sites was completely refractive to EGF stimulation. Overexpression of wt-PTPa [ Fig. 2(F), panel a] or transfection with an empty vector pcDNA3 alone had no effect (data not shown). These results indicate that PKCd positively regulates PTPa activity in EGF-treated BT-20 and SKBR-3 breast cancer cells.
siRNA-mediated PTPa or PKCd knockdown reduces Src activity
We then tested whether PTPa is required for EGF-induced Src activation. We chose BT-20 cells to carry out the study, based on the effectiveness of PTPa2 siRNA to reduce PTPa protein levels (85%-90%) [ Fig. 3(A), panel d] . PTPa suppression by PTPa2 siRNA resulted in loss of Src kinase activation [ Fig. 3(A), panel a] and tyrosine dephosphorylation and anti-pY527/530 immunoblotting revealed no change in Src phosphorylation [ Fig. 3(A), panel b] . By contrast, PTPa2 mutant siRNA did not alter Src kinase activation and inhibit Src phosphorylation [ Fig. 3(A) , panels e and f ]. As expected, PKCd siRNA knockdown reduced Src kinase activity and blocked Src dephosphorylation [ Fig. 3(B) , panels a and b], whereas PKCd mutant siRNA did not [ Fig. 3(B) , panels e and f ]. We therefore conclude that PTPa is a downstream regulator of the EGFR via PKCd activation in BT-20 breast cancer cells.
Since pTyr530 dephosphorylation has also been correlated with elevated PTP1B activity, we also examined the effect of PTP1B on Src kinase activity in BT-20 cells. Although PTP1B knockdown successfully decreased PTP1B protein levels by 75%-85% [ Fig. 3(C), panel d] , it did not alter Src dephosphorylation [ Fig. 3(C) , panels b and f] and activation in BT-20 cells [ Fig. 3(C) , panels a and e]. Therefore, we conclude that PTPa but not PTP1B mediates the activation of Src by EGF in BT-20 breast cancer cells.
PTPa knockdown suppresses colony formation in soft agar
To test the role of PTPa in BT-20 breast cancer cell growth, we transfected cells with PTPa or PTP1B siRNA and compared cell growth. Endogenous PTPa knockdown by PTPa2 siRNA led to a marked reduction of colony formation, whereas control siRNA or PTP1B siRNA had no effect [ Fig. 4(A,B) ]. Together, these results indicate that PTPa is required for EGF-mediated Src activation and cell transformation.
Discussion
In this study, we show that EGF-induced PTPa phosphorylation at Ser180 and Ser204 in BT-20 and SKBR3 breast cancer cell lines results in increased Src kinase activity, due to a decrease in PTPa binding with Grb2 and an increase in PTPa binding with Src. Moreover, EGF-induced PTPa activation and its dissociation from Grb2 is dependent on PKCd. siRNA knockdown of PTPa blocks EGF-mediated Src activation in BT-20 cells. Finally, tumor cell growth and transformation caused by EGF signaling require an integrated EGF/PKC/PTPa/Src pathway. Although the activity of Src is dependent on PTPa in BT-20 and SKBR-3 cancer cells, it is uncertain whether an increase of PTPa activity alone is sufficient to cause Src activation. The activity of PTPa measured by phospho-MBP as substrate increased by 2-2.5 folds after EGF treatment, but the functional relevance of this activation is unclear. In addition, pTyr789 is not increased following EGF treatment in both BT-20 and SKBR3 cells as shown in Fig. 2(A) , panels c and g, suggesting that Grb2 unbound pTyr789 might displace pTyr527 from its intramolecular interaction with Src SH2 domain resulting in pTyr527 dephosphorylation. Because 20% Tyr789 is phosphorylated and most of them are bound to Grb2 in NIH3T3 cells [15] , our data have shown that PTPa-Grb2 binding decreased by more than 60% at 5-10 min after EGF treatment, so there are more than 10% of pTyr789 that are not bound to Grb2. Owing to technical difficulties, we were unable to test the direct dephosphorylation and activation Src by endogenous PTPa. Although we cannot rule out the specific effect of Src activation by PTPa in vitro, it is possible that this action is ectopically elevated in transformed cells. 
EGF induces PTPa and Src activation
Bjorge et al. [31] have shown that PTP1B is the major PTP responsible for regulation of Src in MDA-MB-435s cancer cells. However, we observed that knockdown of PTP1B did not impair EGF signaling and Src activation in BT-20 cancer cells, providing strong evidence that PTP1B is not a Src-specific phosphatase involved in the EGF signaling pathway in these cells. Suppression of endogenous PTPa with PTPa2 siRNA by 20% -30% was observed in SKBR-3 cells. It might be possibly due to SKBR-3 breast cancer cells had no fibroblastic phenotype and cells were to exhibit a transformed phenotype with most of the cells appearing rounded. Thus, a rounded and transformed phenotype of cell might lead to low transfection efficiency.
Overexpression of EGFR family members, including HER2, erbB2, and neu contributes to the progression and development of breast cancer [25, 26] . EGFR is overexpressed in both BT-20 and SKBR-3 (data not shown) cells but not in MDA-MB-231, MDA-MB-435s, MCF-7, or MCF-10A normal breast cancer. It is therefore conceivable that the ability of EGF to induce PTPa-mediated Src activation could be related to the level of EGFR expression in breast cancer cells. Expression of ErbB2/HERs in MCF7 breast cancer cell line results in Src activation via Tyr213 phosphorylation without a corresponding decrease in pY527, suggesting that this is an alternative mechanism by which phosphorylation of this tyrosine residue to disrupt the intramolecular interaction between the C-terminal pTyr527 and the SH2 domain, thereby resulting in Src activation [27] .
In colony formation experiments, the correlation of the levels of EGFR expression and PTPa serine phosphorylation at 180 and/or 204 status: levels of EGFR expression are relatively low in most breast cancer cells compared with normal breast cells [39] . For instance, there are approximately 3-4 folds as much EGFR in BT-20 and SKBR-3 cells as compared with MDA-MB-231, MDA-MB-435, and MCF-7(data not shown) cells. We did not detect any significant increase in Ser180 and/or pSer204 phosphorylation of PTPa after EGF stimulation, whereas we have shown that phosphorylation of these sites increases PTPa catalytic activity towards MBP substrates by 2-2.5 folds. Suppression of endogenous PTPa by siRNA in BT-20 cells results in a 95% decrease in colony formation, both in the absence and presence of EGF [ Fig. 4(A) ]. These data suggest that PTPa siRNA might suppress two different pathways: (1) EGF-mediated PTPa pSer180 and/or pSer204 phosphorylation pathway; (2) EGF independent PTPa-mediated Src activation signaling. PTPa function is regulated and has been shown to be regulated by the combination of both serine and tyrosine phosphorylation [15, 19, 20] . We have previously proposed a model for PTPa-mediated Src activation in which phosphorylated Tyr789 can displaces pTyr527 binding to Src SH2 domain in order to dephosphorylate pTyr527 [7] . Alternatively, other reports have shown that pTyr789-independent activation of Src is able to occur under certain circumstances and in other cell types, i.e. during integrin-mediated cell adhesion [40] or in PC12 cells [40, 41] . It has been suggested that this may be resulted from the displacement of pTyr527 from the SH2 domain by a phosphotyrosine residue in a co-associated protein other then PTPa [42] . In contrast, one report has shown that PTPa does not require pSer204 for Src binding and activation in NIH3T3 and HeLa cells during mitosis, suggesting the existence of alternative mechanisms for Src activation [43] . The reasons for these differences are unknown at this time. PTPa can also be phosphorylated at Ser 202 and Thr 205 [44] , and perhaps other unidentified sites, which might influence the activity of PTPa and its response to EGF treatment.
Suppressing PTPa expression by siRNA in several ER 2 breast cancer cell lines, but not in ER þ breast cancer cells (MCF7 and T47D), can downregulate Src kinase activity and can suppress cellular transformation and apoptosis, suggesting that the function of PTPa is tightly coupled to the maintenance of sufficient Src activity [33] .
In contrast, PTPa may have the opposite effect in other cancer cell types. For example, the ER þ breast cancer MCF7 cell growth and metastasis can be suppressed by the overexpression of PTPa, indicating a negative regulatory role [30] . Many reports have shown that PTPa plays a role in a pro-malignant regulation. Overexpression of PTPa is observed in colon solid tumors [28] and expression of PTPa correlates with gastric cancer progression [45] . Overexpression of PTPa is a general marker for proliferation or de-differentiation in squamous cell carcinoma [29] . In SW480 colon cancer cells, overexpression of PTPa results in activation of Src kinase, leading to cell spreading and invasion [46] . BT-20 is an ER 2 breast cancer cell line [47] and the data presented here are consistent with our previous observation regarding the interdependence between ER status and the requirement of PTPa for survival [33] .
Although Src family kinases are potential therapeutic targets, the large number of protein tyrosine kinases (PTKs) with highly conserved catalytic domains makes the specific targeting extremely challenging. PTPa is an upstream activator of Src and Src family kinases and has a number of advantages as a potential drug target compared with Src. Firstly, knockout of PTPa in mice has few deleterious effects [11, 12] and PTPa siRNA reduces Src kinase activity and causes apoptosis only in certain types of cancer cells, suggesting minimal possibilities for unwanted side effects in humans. Secondly, since PTPa has a specific glycosylated extracellular domain in tumor cells, it may be easier to achieve specific targeting by using humanized antibodies. Furthermore, since Src dephosphorylation and activation in vitro by immuno-purified PTPa greatly depends on the non-enzymatic interaction between Src and PTPa [3, 48] , it may be possible to design small molecules to target PTPa phosphorylation regions and disrupt its interaction with Src.
In summary, we show that EGF can elevate PTPa and Src activities in BT-20 and SKBR-3 breast cancer cells, leading to PTPa-dependent transformation. This is accompanied by the dissociation of PTPa from Grb2 and the formation of a PTPa/Src complex, which is consistent to the phosphotyrosine displacement hypothesis.
